Section 501(a)(2)(B)(21 U.S.C.
351(a)(2)(B)) of the Food, Drug, and Cosmetic Act deems a drug to
be adulterated if the methods used in, or controls used for, its
manufacture, processing, packing, or holding do not conform to or
are not operated or administered in conformity with current good
manufacturing practices. The CGMP regulations implement that
statutory mandate. The agency uses these records to determine
whether the methods, facilities, and controls used in
manufacturing, processing, packing, and holding of drugs conform to
good manufacturing practices. FDA has determine that
these....
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.